Delving into the Latest Updates on Fortunerock (China) Co. Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Endocrinology and Metabolic Disease

Digestive System Disorders

Fusion protein

Colony-stimulating factors

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Fusion protein	4
Colony-stimulating factors	1
Biological products	1

Top 5 Target	Count

EPO receptor(Erythropoietin receptor)	1
IFNα2(Interferon alpha-2)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
OXA1L(OXA1L mitochondrial inner membrane protein)	1
VEGFR(Vascular endothelial growth factor receptor)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Preclinical

Phase 1 Clinical

2

1

Phase 2 Clinical

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Albumin-granulocyte colony stimulating factor(Tianjin Puying Biotechnology Co Ltd) ( CSF-3R )	Neutropenia More	Phase 2
SFR-9216 ( IFNα2 )	Hepatitis B, Chronic More	Phase 1
Albumin-erythropoietin fusion protein(Tianjin Puying Biotechnology Co Ltd) ( EPO receptor )	Anemia of renal disease More	Phase 1
rHSA-GLP-1 (FortuneRock Biotech) ( GLP-1R )	Diabetes Mellitus, Type 2 More	Preclinical
WO2022082906 ( OXA1L )	Neoplasms More	Discovery